Utah is currently home to 1209 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Salt Lake City, Murray, Ogden and West Jordan. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Intervention For AYAS With Cancer Risk Syndromes
NCT04323774
Recruiting
This research is being done because there is a need to improve cancer risk communication and decision-making among adolescents and young adults. In this study, the investigators are looking at whether using a chatbot and online portal for cancer risk information helps improve communication and decision-making. * Over 70,000 adolescents and young adults (AYAs) are diagnosed with cancer in the U.S. every year and up to 10% have genetic changes (or, mutations) that put them at a higher risk of dev... Read More
Gender:
ALL
Ages:
Between 12 years and 24 years
Trial Updated:
01/28/2025
Locations: University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah
Conditions: Cancer Risk Syndrome
Register for Updates
Safety and Efficacy of VDPHL01 in Males and Females with AGA
NCT06527365
Recruiting
This study will evaluate the safety and efficacy of VDPHL01 in male and female subjects with Androgenetic Alopecia (AGA). AGA (or pattern of hair loss) is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormone) that causes hair loss. VDPHL01 8.5 mg Tablets for males and VDPHL01 4.5 mg Tablets for females are an investigational oral drug to treat male and female pattern baldness. This multiple center, open-label, study will last about 13 months and inc... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
01/27/2025
Locations: 02, South Jordan, Utah
Conditions: Androgenetic Alopecia, AGA, Male Pattern Baldness
Register for Updates
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, As a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer
NCT05216432
Recruiting
This is an open-label, FIH study designed to evaluate the maximum tolerated dose, recommended Phase 2 dose, safety, tolerability, PK, pharmacodynamics, and preliminary antineoplastic activity of RLY-2608, in advanced solid tumor patients with a Phosphatidylinositol-4,5-bisphosphate-3 kinase, catalytic subunit alpha (PIK3CA) mutation in blood and/or tumor per local assessment. The study will evaluate RLY-2608 as a single agent for patients with unresectable or metastatic solid tumors. It will als... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/27/2025
Locations: University of Utah- Huntsman Cancer Center, Salt Lake City, Utah
Conditions: PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Unresectable Solid Tumor, Endometrial Cancer
Register for Updates
Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase
NCT05143840
Recruiting
This study is a multicenter Phase 2, non-randomized, open-label single-group frontline study administering asciminib in patients with newly diagnosed Chronic Myeloid Leukemia-Chronic Phase (CML-CP). The aim of this study is to evaluate the efficacy and safety of asciminib in newly diagnosed CML-CP. Patients will receive asciminib 80 mg orally once daily during the single asciminib phase. Response is determined by PCR (polymerase chain reaction) blood test during the study. Patients who have not... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/27/2025
Locations: Huntsman Cancer Institute, Salt Lake City, Utah
Conditions: Chronic Myeloid Leukemia, Chronic Phase, Adult CML, Leukemia, Myeloid, Leukemia,Myeloid, Chronic
Register for Updates
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
NCT03526835
Recruiting
This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC. The dose escalation part has been completed and the RP2D will be further evaluated in an expansion part of the study. Cohorts of selected solid tumor indications for which there is evidence of EGFR dependency and potential sensitivity to EGFR inhibition will be evaluated including head and neck c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/27/2025
Locations: Utah Cancer Specialists, Salt Lake City, Utah
Conditions: Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, NSCLC, HNSCC, Head and Neck Squamous Cell Carcinoma, Esophageal Cancer
Register for Updates
Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors
NCT03141021
Recruiting
First, the investigators plan to use a retrospective analysis to determine the clinical landscape of neurofibromatosis (NF)1-associated malignant peripheral nerve sheath tumor (MPNST) and precursor lesions (e.g., atypical or nodular plexiform neurofibromas). A worldwide database will be established, collecting, in a standardized manner, histologic, immunohistochemical, molecular, radiographic, treatment, and related clinical data from centers worldwide with expertise in these NF1-related cancers... Read More
Gender:
ALL
Ages:
All
Trial Updated:
01/27/2025
Locations: University of Utah, Salt Lake City, Utah
Conditions: Malignant Peripheral Nerve Sheath Tumors
Register for Updates
Study of TTX-MC138 in Subjects With Advanced Solid Tumors
NCT06260774
Recruiting
A Phase 1/2 Multicenter, Open-Label, Dose-Escalation and Expansion Study of TTX MC138 in Subjects with Advanced Solid Tumors
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
01/24/2025
Locations: START Mountain Region, West Valley City, Utah
Conditions: Advanced Solid Tumor
Register for Updates
Prospective Multi-Center Trial for FemBloc Permanent Birth Control
NCT05977751
Recruiting
Prospective, multi-center, international, unblinded, single-arm trial of subjects undergoing FemBloc followed by ultrasound confirmation test.
Gender:
FEMALE
Ages:
Between 21 years and 50 years
Trial Updated:
01/24/2025
Locations: University of Utah, Salt Lake City, Utah
Conditions: Contraception
Register for Updates
Molecular Biology of Polycythemia and Thrombocytosis
NCT00722527
Recruiting
Our study is designed to characterize the clinical picture and genetic pattern of Polycythemia and Thrombocytosis. The purpose of this project is to find a gene and its mutation that causes these disorders. When this is accomplished, new therapies to control and eventually cure the disorder can be designed.
Gender:
ALL
Ages:
All
Trial Updated:
01/23/2025
Locations: University of Utah, Salt Lake City, Utah
Conditions: Polycythemia, Thrombocytosis
Register for Updates
A Study of CYP-001 in Combination with Corticosteroids in Adults with High-risk AGvHD
NCT05643638
Recruiting
This study is a prospective randomized placebo-controlled phase 2 study to compare CYP-001 plus corticosteroids (CS) to placebo plus CS in allogeneic hematologic stem cell transplant recipients with HR-aGvHD. Severity of GvHD will be assessed at screening and throughout the study using Mount Sinai Acute GvHD International Consortium (MAGIC) guidelines. Eligible subjects will be randomized to receive either CYP-001 IV infusion on Days 0 and 4 or placebo on the same days. All subjects will receive... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: University of Utah, Salt Lake City, Utah
Conditions: Graft Versus Host Disease, Acute
Register for Updates
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab
NCT03767348
Recruiting
RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: Eccles Outpatient Care Center- Oncology Clinical Trials, Murray, Utah
Conditions: Cancer, Melanoma (Skin), Mismatch Repair Deficiency, Microsatellite Instability, Non-melanoma Skin Cancer, Cutaneous Melanoma, NSCLC
Register for Updates
Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol
NCT06413433
Recruiting
ENGAGE (Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol) is a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial to assess the efficacy and safety of solriamfetol for the treatment of binge eating disorder (BED) in adults.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
01/21/2025
Locations: Clinical Research Site, Draper, Utah
Conditions: Binge-Eating Disorder
Register for Updates